Kenvue Inc. (NYSE:KVUE) Receives $24.00 Consensus Price Target from Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have been given a consensus rating of “Hold” by the thirteen analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $24.00.

A number of equities analysts recently issued reports on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler upped their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 price objective on the stock. UBS Group lowered their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Finally, Barclays upped their price objective on Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Thursday, March 27th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KVUE. Paloma Partners Management Co bought a new stake in Kenvue in the third quarter valued at about $360,000. Benjamin Edwards Inc. bought a new position in shares of Kenvue during the third quarter worth $1,323,000. Janus Henderson Group PLC grew its holdings in shares of Kenvue by 40.6% in the 3rd quarter. Janus Henderson Group PLC now owns 219,576 shares of the company’s stock valued at $5,080,000 after buying an additional 63,400 shares during the period. Investment Management Corp of Ontario increased its holdings in shares of Kenvue by 48.9% in the third quarter. Investment Management Corp of Ontario now owns 63,627 shares of the company’s stock worth $1,472,000 after acquiring an additional 20,900 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its position in shares of Kenvue by 12.8% during the third quarter. Integrated Wealth Concepts LLC now owns 35,022 shares of the company’s stock worth $810,000 after purchasing an additional 3,962 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 1.7 %

Shares of KVUE stock opened at $21.40 on Friday. The business’s 50 day moving average is $22.60 and its two-hundred day moving average is $22.43. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a market cap of $40.89 billion, a PE ratio of 40.37, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts predict that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.83%. Kenvue’s payout ratio is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.